肺癌合并Trousseau综合征患者的治疗及临床特点
Treatment and Clinical Features in Patients with Lung Cancer Complicated by Trousseau’s Syndrome
DOI: 10.12677/acm.2024.1472021, PDF,   
作者: 隋洺骅, 孙 萍：青岛大学附属烟台毓璜顶医院肿瘤科，山东 烟台；姜 蕾：青岛大学附属烟台毓璜顶医院病理科，山东 烟台
关键词: 肺癌；TKI；Trousseau综合征；脑梗死；癌症治疗；血栓栓塞；Lung Cancer； TKI； Trousseau’s Syndrome； Cerebral Infarction； Cancer Therapy； Thromboembolism
摘要: 目的：探讨特鲁索综合征(Trousseau’s syndrome, TS)的临床表现、治疗及预后。方法与材料：2例渐近性TS发生于1例小细胞肺癌患者和1例表皮生长因子受体(EGFR)突变阳性的非小细胞肺癌(NSCLC)患者。此外，对以往报道的肺癌患者发生TS的典型病例进行分析。结果：我们总结了EGFR突变阳性NSCLC和TS患者的一种可能的治疗选择，酪氨酸激酶抑制剂(TKI)如吉非替尼，然后是奥西替尼，可能有效。对于确诊为小细胞肺癌的患者，还应考虑TS的可能性，必要时应采取抗凝措施。结论：综上所述，这是首个总结肺癌患者TS临床特征的报告，也是首个报道小细胞肺癌合并渐近性TS的病例，以及另一个EGFR突变阳性的NSCLC合并TS的病例。鉴于免疫检查点抑制剂的使用频率越来越高，临床医生应该认识到TS是一种潜在的危及生命的免疫相关不良事件。
Abstract: Aims: The objective of this study is to explore the clinical manifestations, treatment and prognosis of Trousseau’s syndrome (TS). Methods and Material: Two cases of asymptotic TS were developed in a patient with small cell lung cancer and another patient with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). In addition, analysis was performed on the previously reported typical cases of TS that occurred in patients with lung carcinoma. Results: We summarized a possible treatment option for patients with EGFR mutation-positive NSCLC and TS. Tyrosine kinase inhibitor (TKI) such as gefitinib, followed by osimertinib, may be effective. In patients diagnosed with small cell lung cancer, the possibility of TS should also be considered, and anticoagulant measures should be implemented if considered necessary. Conclusions: In conclusion, this is the first report that summarizes the clinical features of cases with TS in Lung cancer patients, as well as reporting the first case of a patient with small cell lung cancer with asymptotic TS, and another with EGFR mutation-positive NSCLC and TS. Clinicians should recognize TS as a potentially life-threatening immune-related adverse event, given the increasing frequency of the use of immune checkpoint inhibitors.
文章引用：隋洺骅, 姜蕾, 孙萍. 肺癌合并Trousseau综合征患者的治疗及临床特点[J]. 临床医学进展, 2024, 14(7): 348-355. https://doi.org/10.12677/acm.2024.1472021

参考文献

[1] Trousseau, A. (1865) Phlegmasia alba dolens. In: Trousseau, A., Seydewitz, M. and Michel P., Eds., Clinique Médicale de L’hôtel-dieu de Paris, J.-B. Baillière et fils, Paris, 654-712.
[2] Sack, G.H., Levin, J. and Bell, W.R. (1977) Trousseauʼs Syndrome and Other Manifestations of Chronic Disseminated Coagulopathy in Patients with Neoplasms. Medicine, 56, 1-37. [Google Scholar] [CrossRef] 
[3] Khorana, A.A. (2010) Venous Thromboembolism and Prognosis in Cancer. Thrombosis Research, 125, 490-493. [Google Scholar] [CrossRef] [PubMed]
[4] Ishikawa, M., Nakayama, K., Ishibashi, T., Sato, E., Nakamura, K., Katagiri, H., et al. (2016) Case Series of Cerebral Infarction with Trousseau’s Syndrome Associated with Malignant Gynecological Tumors. Molecular and Clinical Oncology, 5, 138-142. [Google Scholar] [CrossRef] [PubMed]
[5] Horio, Y., Takamatsu, K., Tamanoi, D., Sato, R., Saruwatari, K., Ikeda, T., et al. (2018) Trousseau’s Syndrome Triggered by an Immune Checkpoint Blockade in a Non‐Small Cell Lung Cancer Patient. European Journal of Immunology, 48, 1764-1767. [Google Scholar] [CrossRef] [PubMed]
[6] Nakao, S., Masuda, T., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Miyamoto, S., et al. (2019) Cerebral Embolism during Edoxaban Administration for Venous Thromboembolism in a Patient with Lung Adenocarcinoma. Medicine, 98, e14821. [Google Scholar] [CrossRef] [PubMed]
[7] Masubuchi, H., Maeno, T., Uchida, M., Kono, S., Suzuki, M., Takemura, M., et al. (2015) A Case of Trousseau Syndrome Caused by Pulmonary Adenocarcinoma That Was Controlled for One Year and 10 Months with Thrombosis Treatment Using an EGFR Tyrosine Kinase Inhibitor and Chemotherapy. Respiratory Medicine Case Reports, 15, 101-105. [Google Scholar] [CrossRef] [PubMed]
[8] Nonagase, Y., Takeda, M., Tanaka, K., Hayashi, H., Iwasa, T. and Nakagawa, K. (2018) Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer Complicated by Trousseau Syndrome with Gefitinib Followed by Osimertinib: A Case Report. Oncotarget, 9, 29532-29535. [Google Scholar] [CrossRef] [PubMed]
[9] Kuwahata, S., Takenaka, T., Yasuda, S., Sakoda, T., Taniyama, H., Nagata, Y., et al. (2017) A Case of Anticoagulant Treatment-Resistant Trousseau Syndrome Controlled by Treatment of the Underlying Lung Adenocarcinoma: Utility of Monitoring D-Dimer Levels. Journal of Cardiology Cases, 15, 65-69. [Google Scholar] [CrossRef] [PubMed]
[10] Varki, A. (2007) Trousseau’s Syndrome: Multiple Definitions and Multiple Mechanisms. Blood, 110, 1723-1729. [Google Scholar] [CrossRef] [PubMed]
[11] Gon, Y., Sakaguchi, M., Takasugi, J. and Mochizuki, H. (2017) Ischemic Stroke in Cancer Patients Treated with Direct Oral Anticoagulants for Venous Thromboembolism. Thrombosis Research, 154, 16-18. [Google Scholar] [CrossRef] [PubMed]
[12] Grover, S.P. and Mackman, N. (2020) Tissue Factor in Atherosclerosis and Atherothrombosis. Atherosclerosis, 307, 80-86. [Google Scholar] [CrossRef] [PubMed]
[13] Jiang, P., Xue, D., Zhang, Y., Ye, L., Liu, Y., Makale, M., et al. (2014) The Extrinsic Coagulation Cascade and Tissue Factor Pathway Inhibitor in Macrophages: A Potential Therapeutic Opportunity for Atherosclerotic Thrombosis. Thrombosis Research, 133, 657-666. [Google Scholar] [CrossRef] [PubMed]
[14] Kunimasa, K., Nishino, K., Kimura, M., Inoue, T., Tamiya, M., Kumagai, T., et al. (2018) Pembrolizumab-Induced Acute Thrombosis. Medicine, 97, e10772. [Google Scholar] [CrossRef] [PubMed]
[15] Buonerba, C., Iaccarino, S., Dolce, P., Pagliuca, M., Izzo, M., Scafuri, L., et al. (2019) Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 11, Article 1259. [Google Scholar] [CrossRef] [PubMed]
[16] Sørensen, H.T., Mellemkjær, L., Olsen, J.H. and Baron, J.A. (2000) Prognosis of Cancers Associated with Venous Thromboembolism. New England Journal of Medicine, 343, 1846-1850. [Google Scholar] [CrossRef] [PubMed]
[17] El-Shami, K., Griffiths, E. and Streiff, M. (2007) Nonbacterial Thrombotic Endocarditis in Cancer Patients: Pathogenesis, Diagnosis, and Treatment. The Oncologist, 12, 518-523. [Google Scholar] [CrossRef] [PubMed]
[18] Nishino, W., Tajima, Y., Inoue, T., Hayasaka, M., Katsu, B., Ebihara, K., et al. (2017) Severe Vasospasm of the Middle Cerebral Artery after Mechanical Thrombectomy Due to Infective Endocarditis: An Autopsy Case. Journal of Stroke and Cerebrovascular Diseases, 26, e186-e188. [Google Scholar] [CrossRef] [PubMed]
[19] Ladizinski, B. and Federman, D.G. (2012) Trousseau Syndrome. Canadian Medical Association Journal, 185, 1063. [Google Scholar] [CrossRef] [PubMed]
[20] Wahrenbrock, M., Borsig, L., Le, D., Varki, N. and Varki, A. (2003) Selectin-Mucin Interactions as a Probable Molecular Explanation for the Association of Trousseau Syndrome with Mucinous Adenocarcinomas. Journal of Clinical Investigation, 112, 853-862. [Google Scholar] [CrossRef] [PubMed]
[21] Key, N.S. (2015) New Players in Trousseau Syndrome. Blood, 126, 1270-1272. [Google Scholar] [CrossRef] [PubMed]
[22] Ikushima, S., Ono, R., Fukuda, K., Sakayori, M., Awano, N. and Kondo, K. (2015) Trousseau’s Syndrome: Cancer-Associated Thrombosis. Japanese Journal of Clinical Oncology, 46, 204-208. [Google Scholar] [CrossRef] [PubMed]
[23] Phillips, K.G., Lee, A.M., Tormoen, G.W., Rigg, R.A., Kolatkar, A., Luttgen, M., et al. (2015) The Thrombotic Potential of Circulating Tumor Microemboli: Computational Modeling of Circulating Tumor Cell-Induced Coagulation. American Journal of Physiology-Cell Physiology, 308, C229-C236. [Google Scholar] [CrossRef] [PubMed]
[24] Qu, Y., Che, N., Zhao, D., Zhang, C., Su, D., Zhou, L., et al. (2015) The Clinicopathological Significance of ALK Rearrangements and KRAS and EGFR Mutations in Primary Pulmonary Mucinous Adenocarcinoma. Tumor Biology, 36, 6417-6424. [Google Scholar] [CrossRef] [PubMed]
[25] Kim, E.S., Baran, A.M., Mondo, E.L., Rodgers, T.D., Nielsen, G.C., Dougherty, D.W., et al. (2017) Risk of Thromboembolism in Cisplatin versus Carboplatin-Treated Patients with Lung Cancer. PLOS ONE, 12, e0189410. [Google Scholar] [CrossRef] [PubMed]
[26] Takeda, M., Okamoto, I. and Nakagawa, K. (2014) Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib. Journal of Thoracic Oncology, 9, 200-204. [Google Scholar] [CrossRef] [PubMed]
[27] Ke, E., Zhou, Q., Zhang, Q., Su, J., Chen, Z., Zhang, X., et al. (2017) A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. Journal of Thoracic Oncology, 12, 1368-1375. [Google Scholar] [CrossRef] [PubMed]
[28] Zhou, J. and Ben, S. (2017) Comparison of Therapeutic Effects of EGFR‐Tyrosine Kinase Inhibitors on 19Del and L858R Mutations in Advanced Lung Adenocarcinoma and Effect on Cellular Immune Function. Thoracic Cancer, 9, 228-233. [Google Scholar] [CrossRef] [PubMed]
[29] Zhang, Y., Ma, Y., Li, Y., Shen, X., Yu, Y., Pan, Y., et al. (2017) Are Exon 19 Deletions and L858R Different in Early Stage Lung Adenocarcinoma? Journal of Cancer Research and Clinical Oncology, 144, 165-171. [Google Scholar] [CrossRef] [PubMed]
[30] Oya, Y., Yoshida, T., Kuroda, H., Shimizu, J., Horio, Y., Sakao, Y., et al. (2017) Association between EGFR T790M Status and Progression Patterns during Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation. Clinical Lung Cancer, 18, 698-705.E2. [Google Scholar] [CrossRef] [PubMed]
[31] Kawamura, T., Kenmotsu, H., Omori, S., Nakashima, K., Wakuda, K., Ono, A., et al. (2018) Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 19, e247-e252. [Google Scholar] [CrossRef] [PubMed]
[32] Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., et al. (2018) Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Annals of Oncology, 29, iv192-iv237. [Google Scholar] [CrossRef] [PubMed]
[33] Streiff, M.B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P.L., Chesney, C., et al. (2018) NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. Journal of the National Comprehensive Cancer Network, 16, 1289-1303. [Google Scholar] [CrossRef] [PubMed]
[34] O’Connell, C., Escalante, C.P., Goldhaber, S.Z., McBane, R., Connors, J.M. and Raskob, G.E. (2020) Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. The Oncologist, 26, e8-e16. [Google Scholar] [CrossRef] [PubMed]
[35] Cestari, D.M., Weine, D.M., Panageas, K.S., Segal, A.Z. and DeAngelis, L.M. (2004) Stroke in Patients with Cancer. Neurology, 62, 2025-2030. [Google Scholar] [CrossRef] [PubMed]
[36] Umemura, T., Yamamoto, J., Akiba, D. and Nishizawa, S. (2017) Bilateral Cerebral Embolism as a Characteristic Feature of Patients with Trousseau Syndrome. Journal of Clinical Neuroscience, 42, 155-159. [Google Scholar] [CrossRef] [PubMed]

为你推荐